Bring manufacturers, ingredient innovators, regulators, and clinicians together to forge a single, globally resonant pathway for advancing novel infant formula ingredients, uniting efficacy evidence, regulatory foresight, and cross‑industry collaboration into one strategic discussion.

• Define what truly moves a submission forward globally by aligning on essential evidence requirements, shared regulatory pain points, and practical opportunities to avoid redundant studies while meeting expectations across regions
• Shape forward‑looking approval strategies by anticipating unspoken regulatory concerns, learning from stalled innovations, and leveraging smarter preclinical, mechanistic, and phased‑trial designs that reduce risk and accelerate progress
• Strengthen cross‑industry collaboration for long‑term resilience with open dialogue between manufacturers and ingredient providers, identifying adaptable solutions, translating efficacy into credible claims, and preparing for the evolving oversight landscape driven by emerging government initiatives